Biomarkers for characterization of heart failure – Distinction of heart failure with preserved and reduced ejection fraction

Sinning, Christoph; Kempf, Tibor; Schwarzl, Michael; Lanfermann, Simon; Ojeda, Francisco; Schnabel, Renate B.; Zengin, Elvin; Wild, Philipp S.; Lackner, K. J.; Münzel, Thomas; Blankenberg, Stefan; Wollert, Kai C.; Zeller, Tanja; Westermann, Dirk

doi:10.1016/j.ijcard.2016.11.110

Cited by 58 publications

(54 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, soluble suppression of tumorigenicity 2 (sST2), a member of the interleukin (IL)-1 receptor family, has emerged to be a promising marker of myocardial stress 7. Thus, it has been shown to be predictive of adverse clinical outcomes in different cardiovascular diseases, such as stable coronary artery disease,8 acute coronary syndrome,9 and acute10 as well as chronic heart failure 11…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Tse

Luk

et al. 2018

Heart Asia

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Tse

Luk

et al. 2018

Heart Asia

View full text Add to dashboard Cite

show abstract

“…The combination of several biomarkers which encompass multiple pathophysiological features of HFpEF may have greater predictive value than individual biomarkers alone. One study combining NT-proBNP, sST2, GDF-15 and C-reactive protein demonstrated good discriminatory value between diagnosing HFpEF and HFrEF [73]. Genetic profiling of HFpEF subjects has demonstrated 344 microRNAs to have altered expression compared to HFrEF and control groups [74].…”

Section: Future Directionsmentioning

confidence: 99%

Biomarkers in Heart Failure With Preserved Ejection Fraction: An Update on Progress and Future Challenges

Carnes

Gordon

2020

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…Finally, it seems likely that measurement of inflammatory biomarkers (e.g. C‐reactive protein, growth differentiation factor‐15 and suppression of tumorigenicity 2) as well as adipocytokines (leptin, resistin, interleukin‐6 and tumour necrosis factor receptor) might identify the striking adipose tissue dysfunction seen in HFpEF, but not HVHF or HOHF . Further studies are needed to support this hypothesis.…”

Section: Characterizing Obesity‐related Cardiac Enlargement In Clinicmentioning

confidence: 99%

The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range

Packer

2018

European J of Heart Fail

View full text Add to dashboard Cite

Patients with obesity, a reduced exercise capacity, increased cardiac filling pressures and a measured left ventricular ejection fraction in the normal range do not have a homogeneous disorder, but instead, exhibit one of three phenotypes. First, many obese people exhibit sodium retention, plasma volume expansion and cardiac enlargement, and some are likely to have heart failure that is related to hypervolaemia, even though cardiac index and circulating levels of natriuretic peptides are not meaningfully increased. Second, in some middle‐aged men and women (particularly those with minimal co‐morbidities), levels of natriuretic peptides increase markedly and can lower systemic vascular resistance, thus leading to high‐output heart failure (HOHF) and glomerular hyperfiltration. Third, older obese people, particularly women with multiple co‐morbidities, exhibit the syndrome of heart failure with a preserved ejection fraction (HFpEF). Despite degrees of plasma volume expansion similar to HOHF, these patients exhibit only modestly increased ventricular dimensions and circulating levels of natriuretic peptides (despite a high prevalence of atrial fibrillation), and glomerular function is characteristically impaired. A conceptual framework is proposed to distinguish among the three phenotypes seen in obese patients with exercise intolerance, increased ventricular filling pressures and a measured left ventricular ejection fraction in the normal range, since they may respond differently to therapeutic interventions. Efforts are needed to enhance the recognition of heart failure in obese people and to ensure that clinical trials that are designed to study patients with HFpEF actually enrol those who have the disease.

show abstract

Biomarkers for characterization of heart failure – Distinction of heart failure with preserved and reduced ejection fraction

Cited by 58 publications

References 28 publications

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Biomarkers in Heart Failure With Preserved Ejection Fraction: An Update on Progress and Future Challenges

The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range

Contact Info

Product

Resources

About